Intended for healthcare professionals
HIS news
ClinicalTrials.gov lists the phase 2b dose-ranging study of EVO756 in adults with moderate-to-severe chronic spontaneous urticaria as completed. The randomized, placebo-controlled study enrolled 182 participants. Results have not been posted in the registry.
Read news →
HIS news
A pooled analysis of REMIX-1 and REMIX-2 found similar overall adverse-event frequencies with remibrutinib and placebo, but higher bleeding-event frequencies with remibrutinib. The imbalance was driven by predominantly mild petechia and related mucocutaneous events.
Read news →
HIS news
A systematic review confirms that sleep disturbance is a prevalent and clinically significant comorbidity in chronic spontaneous urticaria (CSU), correlating with disease activity, psychosocial burden, and emerging circadian-immune biomarker abnormalities. Findings support incorporating routine sleep assessment into comprehensive CSU management.
Read news →
HIS news
A global, randomized, double-blind phase 3b trial is assessing remibrutinib 25 mg twice daily against placebo and omalizumab 300 mg every 4 weeks in adults with chronic spontaneous urticaria inadequately controlled by second-generation H1-antihistamines. The trial includes a 52-week core phase and an optional open-label extension evaluating up to two years of remibrutinib exposure.
Read news →
HIS news
A randomized, double-blind, placebo-controlled phase 2 dose-ranging trial evaluating oral rilzabrutinib (SAR444671) in adults with moderate-to-severe chronic spontaneous urticaria inadequately controlled by H1 antihistamines has reached completion. The Sanofi-sponsored study assessed three dose levels over 12 weeks, followed by a 40-week open-label extension.
Read news →
HIS news
Pfizer has launched a randomized, double-blind, placebo-controlled Phase 2b trial evaluating oral ritlecitinib (50 mg and 100 mg once daily) in adults with chronic spontaneous urticaria inadequately controlled by second-generation antihistamines. Approximately 150 participants will be enrolled across a 24-week double-blind treatment period.
Read news →